Suppr
超能文献

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

作者信息

Mesa R A, Tefferi A, Li C-Yang, Steensma D P

出版信息

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.

DOI:10.1038/sj.leu.2404398

PMID:16990762

Abstract

摘要

相似文献

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.

Leuk Lymphoma. 2010 Oct;51(10):1941-3. doi: 10.3109/10428194.2010.506567.

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.

Leuk Res. 2011 Jun;35(6):e69-70. doi: 10.1016/j.leukres.2010.12.019. Epub 2011 Jan 12.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.

Leuk Lymphoma. 2017 Oct;58(10):2511-2513. doi: 10.1080/10428194.2017.1295146. Epub 2017 Feb 28.

Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.

Ann Hematol. 2016 Feb;95(3):525-7. doi: 10.1007/s00277-015-2584-8. Epub 2016 Jan 11.

Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).

Leuk Res. 2010 Jul;34(7):e169-72. doi: 10.1016/j.leukres.2009.12.015. Epub 2010 Jan 31.

Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.

Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).

Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.

引用本文的文献

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Cancers (Basel). 2025 Apr 22;17(9):1388. doi: 10.3390/cancers17091388.

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Cells. 2022 Feb 5;11(3):553. doi: 10.3390/cells11030553.

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31.

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Onco Targets Ther. 2014 Jun 13;7:1043-50. doi: 10.2147/OTT.S59628. eCollection 2014.

Thalidomide treatment in a myelofibrosis patient with leukemia transformation.

Int J Hematol. 2014 Feb;99(2):188-92. doi: 10.1007/s12185-013-1478-6. Epub 2013 Dec 4.

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):341-4. doi: 10.1016/j.clml.2012.04.001. Epub 2012 May 10.

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

Blood. 2011 Jul 21;118(3):523-8. doi: 10.1182/blood-2011-02-337303. Epub 2011 May 6.

Initial testing of lenalidomide by the pediatric preclinical testing program.

Pediatr Blood Cancer. 2011 Oct;57(4):606-11. doi: 10.1002/pbc.22877. Epub 2011 Feb 25.

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.

Cancer Immunol Immunother. 2008 Dec;57(12):1849-59. doi: 10.1007/s00262-008-0512-7. Epub 2008 Apr 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译